A PHASE II, OPEN-LABEL, MULTICENTER STUDY EVALUATING THE SAFETY AND EFFICACY OF NEOADJUVANT AND ADJUVANT TIRAGOLUMAB PLUS ATEZOLIZUMAB, WITH OR WITHOUT PLATINUM-BASED CHEMOTHERAPY, IN PATIENTS WITH PREVIOUSLY UNTREATED LOCALLY ADVANCED RESECTABLE STAGE II, IIIA, OR SELECT IIIB NON-SMALL CELL LUNG CANCER

  • Markman, Ben (Primary Chief Investigator (PCI))

Project: Research

Project Details

StatusActive
Effective start/end date26/09/22 → 25/09/25

Keywords

  • Clinical trial
  • Lung cancer
  • Oncology